Deutsche Bank AG lowered its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 46.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 323,592 shares of the medical equipment provider’s stock after selling 279,312 shares during the period. Deutsche Bank AG owned 0.16% of Zimmer Biomet worth $42,536,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in Zimmer Biomet by 9.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock worth $1,524,453,000 after buying an additional 1,033,717 shares during the last quarter. Calamos Advisors LLC boosted its stake in Zimmer Biomet by 6.8% in the 3rd quarter. Calamos Advisors LLC now owns 36,675 shares of the medical equipment provider’s stock worth $4,822,000 after buying an additional 2,322 shares during the last quarter. Flinton Capital Management LLC boosted its stake in Zimmer Biomet by 8.0% in the 2nd quarter. Flinton Capital Management LLC now owns 12,444 shares of the medical equipment provider’s stock worth $1,387,000 after buying an additional 918 shares during the last quarter. Schroder Investment Management Group boosted its stake in Zimmer Biomet by 71.5% in the 2nd quarter. Schroder Investment Management Group now owns 64,996 shares of the medical equipment provider’s stock worth $7,233,000 after buying an additional 27,096 shares during the last quarter. Finally, Palladium Partners LLC acquired a new stake in Zimmer Biomet in the 3rd quarter worth about $254,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have issued reports on ZBH. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Oppenheimer set a $135.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a research note on Thursday, December 6th. UBS Group began coverage on Zimmer Biomet in a research note on Tuesday, November 27th. They issued a “buy” rating and a $140.00 price target on the stock. Leerink Swann decreased their price target on Zimmer Biomet from $146.00 to $141.00 and set an “outperform” rating on the stock in a research note on Monday, October 29th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet in a research note on Monday, August 27th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the stock. Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $134.90.

In other news, VP Chad F. Phipps sold 30,100 shares of Zimmer Biomet stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.71% of the company’s stock.

NYSE ZBH opened at $107.25 on Tuesday. The stock has a market capitalization of $22.23 billion, a PE ratio of 13.36, a PEG ratio of 2.21 and a beta of 1.16. Zimmer Biomet Holdings Inc has a 1-year low of $104.28 and a 1-year high of $134.55. The company has a current ratio of 1.89, a quick ratio of 0.96 and a debt-to-equity ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.03. The business had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The company’s revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 EPS. Sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.64 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 31st. Stockholders of record on Friday, December 28th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.90%. The ex-dividend date is Thursday, December 27th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.

TRADEMARK VIOLATION WARNING: “Deutsche Bank AG Has $42.54 Million Position in Zimmer Biomet Holdings Inc (ZBH)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2018/12/18/deutsche-bank-ag-has-42-54-million-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.